Japan· JP-4291403A2149
カルボプラチン
A carboplatin product containing カルボプラチン, registered in Japan by ヴィアトリス・ヘルスケア, on the national reimbursement list. The same ATC class is registered in 17 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Carboplatin is registered in 17 of 19 countries.
Countries holding a registration under ATC L01XA02 (carboplatin), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 9 of them publish a price we can compare per daily dose
Carboplatin · ATC L01XA02
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of carboplatin costs, country by country.
Normalised to the WHO defined daily dose (25 mg), the median price runs from $0.34 in Czechia to $7.73 in Switzerland — a ×23 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Carboplatin · price per daily dose (25 mg)
USD · FX 28 Sept 2026
- CH Switzerland$7.73
- CZ Czechia$0.34
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- カルボプラチン
- Manufacturer
- ヴィアトリス・ヘルスケア
- Country
- Japan (JP)
- ATC code
- L01XA02
- ATC class
- Carboplatin
- Defined daily dose
- 25 mg, P
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
564 interactions on record for carboplatin.
Graded by severity as the source publishes them — 37 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Carboplatin · interactions on record
564 records
- 37 severe
- 205 moderate
- 15 minor
- 307 info
Most severe, free to view
- CidofovirJ05AB12severe
- ThiotepaL01AC01severe
- CladribineL01BB04severe
- TopotecanL01CE01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01XA02
Carboplatin, as other registers publish it.
- GermanyCarbo-CellStadapharm Gmbh
- GermanyCarbo-Cell®Stadapharm Gmbh
- FinlandCarboloxJacobsen Pharma AS
- GermanyCarbomedacMedac Gesellschaft Für Klinische Spezialpräparate Mbh (Wedel)
- PolandCarbomedacmedac Gesellschaft fur klinische Specialpraparate mbH
- DenmarkCarbomedacMedac Gesellschaft fuer klinische Spezialpraeparate mbH
- FinlandCarbomedacMedac Gesellschaft Für Klinische Spezialpräparate mbH
- GermanyCarboplatOnkovis Gmbh
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b375be69-d2e5-45db-9ebe-e85c93579c42 GET /v1/drugs/b375be69-d2e5-45db-9ebe-e85c93579c42?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "１５０ｍｇ１５ｍＬ１瓶",
"marks": "局",
"source": "mhlw",
"remarks": null,
"yj_code": "4291403A2149",
"category": "注射薬",
"price_yen": 3058,
"generic_name": "カルボプラチン",
"product_name_jp": null,
"therapeutic_class": "4291",
"transitional_expiry": null
}See everything about carboplatin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.